News - Appili Therapeutics

NEWS

Highlights

News Highlights

Check this page for recent news from Appili Therapeutics.

September 27, 2023

Appili Therapeutics Announces Results of Annual Meeting of Shareholders and Provides Corporate Update

September 27, 2023

Appili Therapeutics Presents at the 10th International Tularemia Conference

September 25, 2023

Appili Therapeutics Announces U.S. FDA Approval of LIKMEZ™ (ATI-1501) Metronidazole Oral Suspension

August 11, 2023

Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2024

June 29, 2023

Appili Therapeutics Announces Bridge Loan from Bloom Burton & Co.

June 23, 2023

Appili Therapeutics Reports Fiscal Year 2023 Financial and Operational Results

May 24, 2023

Appili Therapeutics Announces Issuance of Patent for ATI-1501 Liquid Oral Reformulation of Metronidazole

May 8, 2023

Appili Therapeutics Secures Contract for ATI-1701 Funding from the U.S. Air Force Academy

April 18, 2023

Appili Therapeutics to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference

April 3, 2023

Appili Therapeutics Appoints Dr. Gary Nabors as Chief Development Officer

March 20, 2023

Appili Therapeutics Announces Additional Funding of CAD$2.5 million under Non-Convertible Secured Loan with Long Zone Holdings

February 14, 2023

Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2023

February 8, 2023

Appili Therapeutics Announces that FDA accepts the ATI-1501 NDA

January 17, 2023

Appili Therapeutics Appoints Dr. Carl Gelhaus and Arthur Baran to support the ATI-1701 Biodefense Vaccine Program

January 13, 2023

Appili Therapeutics Announces Notice of Allowance from the U.S. Patent and Trademark Office for ATI-1501 Liquid Oral Reformulation of Metronidazole